CHROMR and multiple sclerosis: Interestingly, when patients with multiple sclerosis were split into a relapsing-phase group (n = 19) and a remitting-phase group (n = 19), the remitting-phase group had increased CHROMR expression levels, indicating a beneficial effect for CHROMR during disease progression [23], and potentially identifying CHROMR to be a biomarker for multiple sclerosis.